John G Ullman & Associates Inc Amgen Inc Transaction History

John G Ullman & Associates Inc

$649 Million
Q3 2024

A detailed history of John G Ullman & Associates Inc transactions in Amgen Inc stock. As of the latest transaction made, John G Ullman & Associates Inc holds 9,350 shares of AMGN stock, worth $2.62 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares

9,350

Previous 10,464 10.65%

Holding current value

$2.62 Million

Previous $3.27 Million 7.86%

% of portfolio

0.46%

Previous 0.52%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$309.38 - $337.38 $344,649 - $375,841	-1,114 Reduced 10.65%	9,350 $3.01 Million
Q1 2024 May 06, 2024	SELL	$268.87 - $324.56 $94,104 - $113,596	-350 Reduced 3.24%	10,464 $2.98 Million
Q4 2023 Jan 31, 2024	SELL	$255.7 - $288.46 $33,241 - $37,499	-130 Reduced 1.19%	10,814 $3.11 Million
Q3 2023 Nov 01, 2023	SELL	$218.65 - $271.46 $10,932 - $13,572	-50 Reduced 0.45%	10,944 $2.94 Million
Q2 2023 Aug 21, 2023	SELL	$214.27 - $253.37 $20,141 - $23,816	-94 Reduced 0.85%	10,994 $2.44 Million
Q1 2023 May 05, 2023	SELL	$225.79 - $275.2 $28,675 - $34,950	-127 Reduced 1.13%	11,088 $2.68 Million
Q4 2022 Feb 08, 2023	BUY	$229.03 - $291.01 $17,177 - $21,825	75 Added 0.67%	11,215 $2.95 Million
Q3 2022 Oct 19, 2022	SELL	$224.46 - $253.15 $11,223 - $12,657	-50 Reduced 0.45%	11,140 $2.51 Million
Q1 2022 Apr 29, 2022	SELL	$219.27 - $242.57 $24,119 - $26,682	-110 Reduced 0.97%	11,190 $2.71 Million
Q4 2021 Jan 26, 2022	BUY	$198.88 - $227.6 $916,836 - $1.05 Million	4,610 Added 68.91%	11,300 $2.54 Million
Q1 2021 Apr 22, 2021	SELL	$221.91 - $258.6 $332,865 - $387,900	-1,500 Reduced 18.32%	6,690 $1.67 Million
Q3 2020 Nov 06, 2020	SELL	$234.65 - $260.95 $1,173 - $1,304	-5 Reduced 0.06%	8,190 $2.08 Million
Q2 2020 Jul 29, 2020	BUY	$197.81 - $242.74 $989 - $1,213	5 Added 0.06%	8,195 $1.93 Million
Q4 2019 Jan 29, 2020	SELL	$189.21 - $243.2 $649,368 - $834,662	-3,432 Reduced 29.53%	8,190 $1.97 Million
Q2 2019 Aug 02, 2019	BUY	$166.7 - $195.41 $28,672 - $33,610	172 Added 1.5%	11,622 $2.14 Million
Q1 2019 Apr 30, 2019	SELL	$180.87 - $203.88 $18,087 - $20,388	-100 Reduced 0.87%	11,450 $2.18 Million
Q4 2018 Jan 29, 2019	SELL	$178.4 - $208.25 $16,591 - $19,367	-93 Reduced 0.8%	11,550 $2.25 Million
Q3 2018 Nov 02, 2018	BUY	$185.29 - $208.89 $18,529 - $20,889	100 Added 0.87%	11,643 $2.41 Million
Q2 2018 Jul 23, 2018	SELL	$166.05 - $186.51 $2,490 - $2,797	-15 Reduced 0.13%	11,543 $2.13 Million
Q1 2018 Apr 19, 2018	SELL	$169.43 - $198.0 $177,901 - $207,900	-1,050 Reduced 8.33%	11,558 $1.97 Million
Q4 2017 Jan 31, 2018	SELL	$168.79 - $188.59 $25,318 - $28,288	-150 Reduced 1.18%	12,608 $2.19 Million
Q3 2017 Nov 03, 2017	BUY	$167.29 - $191.0 $2.13 Million - $2.44 Million	12,758	12,758 $2.38 Million

Others Institutions Holding AMGN

# of Institutions

3,123

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $150B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of John G Ullman & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on John G Ullman & Associates Inc with notifications on news.

Account

John G Ullman & Associates Inc Amgen Inc Transaction History